Schiff Nutrition International, Inc., (NYSE: WNI), announced today it has appointed three new members to its recently-established Scientific Advisory Board: Dale Bredesen, MD; Michael A. Fischbach, Ph.D.; and Charles N. Serhan, Ph.D. Dr. Richard H. Carmona, 17th Surgeon General of the United States, currently serves as chair of the Scientific Advisory Board.

Tarang Amin, president and chief executive officer of Schiff Nutrition, stated: “The Scientific Advisory Board has been established to play a key role in our efforts to lead innovation. These three additions strengthen and diversify the expertise from which to draw as we pursue new product development. We look forward to the guidance of Dr. Bredesen in aging and age-associated diseases, Dr. Fischbach in probiotics and Dr. Serhan in inflammation. This is all complemented by Dr. Carmona’s background as one of the world’s leading experts in public health.”

Dale Bredesen, MD is Professor and Founding President of the Buck Institute for Age Research, the nation’s only independent research institute focused on aging and age-associated disease, and Adjunct Professor, Department of Neurology, UCSF. Dr. Bredesen is a member of the National Advisory Council on Aging, the Society for Neuroscience, and the American Society for Biochemistry and Molecular Biology. He has co-authored over 180 scientific papers and three books. He received his undergraduate degree from Caltech and his MD from Duke University School of Medicine.

Michael Fischbach, Ph.D. is an Assistant Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF and a member of the California Institute of Quantitative Biosciences. Fischbach is a recipient of the NIH Director's New Innovator Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research award from the W.M. Keck Foundation, and the Young Investigator Grant for Probiotics Research from the Global Probiotics Council. Fischbach worked at Harvard University in the laboratories of Christopher Walsh and David Liu and spent two years as an independent fellow at Massachusetts General Hospital coordinating a collaborative effort based at the Broad Institute to develop genomics-based approaches to the discovery of small molecules from microbes. Fischbach received his Ph.D. in chemistry from Harvard University.

Charles N. Serhan, Ph.D. is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School, a Professor in the Department of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine and an Affiliate Faculty Member of MIT. Dr. Serhan was appointed to the Harvard Faculty in 1986 and has served as Senior Biochemist in Medicine at Brigham and Women’s Hospital since 1992. An author of 346 publications, he has received a number of awards and honors, including a MERIT Award from the National Institute of General Medical Sciences and an honorary degree from Harvard University. Dr. Serhan received degrees in Biochemistry from Stony Brook University, Experimental Pathology and Medical Sciences at the New York University School of Medicine, as well as post-doctoral training in Physiological Chemistry at the Karolinska Institute Medical University in Stockholm, Sweden.

About Schiff Nutrition

Schiff Nutrition International, Inc. develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the United States and throughout the world. Schiff’s portfolio of well-known brands includes Schiff Move Free®, Schiff® Vitamins, Schiff MegaRed®, Schiff Mega-D3®, Tiger's Milk®, Schiff Sustenex®, and Schiff Digestive Advantage®. To learn more about Schiff, please visit the web site www.schiffnutrition.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based on management’s beliefs and assumptions, current expectations, estimates, and projections. These statements are subject to known and unknown risks and uncertainties, certain of which are beyond the company’s ability to control or predict, and therefore, actual results may differ materially. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date hereof. Schiff Nutrition disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. You are cautioned not to place undue reliance on these forward-looking statements.

Important factors that may cause actual results of Schiff Nutrition to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: members of our Scientific Advisory Board may not continue service, dependence on sales of Schiff Move Free product and the joint care category, dependence on sales of Schiff MegaRed product, dependence on individual customers, adverse publicity or consumer perception regarding our nutritional supplements and/or their ingredients, similar products distributed by other companies or the nutritional supplement industry generally, the impact of competitive products and pricing pressure (including expansion of private label products), the inability to successfully bid on new and existing private label business, the impact of raw material pricing, availability and quality (particularly relating to joint care products and ingredients from third-party suppliers outside the United States, including China), claims that our products infringe the intellectual property rights of others, the inability to enforce or protect our intellectual property rights and proprietary techniques against infringement, the inability to successfully launch and maintain sales (especially in the joint care and omega-3 categories) outside of the United States while maintaining the integrity of the products sold and complying with local regulations, the inability to appropriately respond to changing consumer preferences and demand for new products, the inability to gain or maintain market distribution for new products or product enhancements, including products in the probiotic space, litigation and government or administrative regulatory action in the United States and internationally, including FDA enforcement and product liability claims, the inability or increased cost to obtain sufficient levels of product liability and general insurance, the inability to comply with existing or new regulations, both in the United States and abroad, and adverse actions regarding product formulation, claims or advertising, product recalls or a significant amount of product returns, dependence on a single manufacturing facility and potential disruptions of our manufacturing operations, the inability to find strategic transaction opportunities or the inability to successfully consummate or integrate a strategic transaction (including the inability to successfully integrate the assets recently acquired from Ganeden), the inability to maintain or attract key personnel, interruptions to our information technology systems, control by our principal stockholders, and other factors indicated from time to time in the company’s SEC reports, copies of which are available upon request from the company’s investor relations department or may be obtained at the SEC's web site (www.sec.gov). These risks and uncertainties should be carefully considered before making an investment decision with respect to shares of our common stock.